Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Sex Cord-Gonadal Stromal Tumors | 7 | 2024 | 118 | 4.090 |
Why?
|
Ovarian Neoplasms | 14 | 2024 | 4907 | 2.290 |
Why?
|
Uterine Neoplasms | 5 | 2024 | 1427 | 1.940 |
Why?
|
Solitary Fibrous Tumors | 2 | 2022 | 70 | 1.470 |
Why?
|
Granulosa Cell Tumor | 3 | 2024 | 77 | 1.240 |
Why?
|
Cystadenocarcinoma, Serous | 4 | 2024 | 480 | 1.030 |
Why?
|
Enchondromatosis | 1 | 2024 | 14 | 0.950 |
Why?
|
Embryoid Bodies | 1 | 2024 | 65 | 0.900 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2024 | 710 | 0.890 |
Why?
|
Thecoma | 1 | 2023 | 11 | 0.870 |
Why?
|
Sertoli Cell Tumor | 1 | 2023 | 36 | 0.850 |
Why?
|
Uterine Cervical Neoplasms | 6 | 2024 | 2044 | 0.820 |
Why?
|
Endometrial Stromal Tumors | 1 | 2023 | 46 | 0.810 |
Why?
|
Adenosarcoma | 1 | 2022 | 36 | 0.800 |
Why?
|
Sarcoma, Endometrial Stromal | 1 | 2023 | 93 | 0.790 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 2 | 2024 | 494 | 0.780 |
Why?
|
Endometrial Neoplasms | 4 | 2024 | 1382 | 0.760 |
Why?
|
Rhabdomyosarcoma, Embryonal | 1 | 2022 | 99 | 0.760 |
Why?
|
Peritoneum | 1 | 2022 | 231 | 0.750 |
Why?
|
Teratoma | 1 | 2024 | 405 | 0.740 |
Why?
|
Fibroma | 1 | 2021 | 201 | 0.680 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2022 | 249 | 0.670 |
Why?
|
Cysts | 1 | 2024 | 685 | 0.630 |
Why?
|
Lymphoma, Extranodal NK-T-Cell | 1 | 2018 | 48 | 0.610 |
Why?
|
Rhinitis, Allergic, Seasonal | 1 | 2018 | 104 | 0.600 |
Why?
|
Cell Transformation, Viral | 1 | 2019 | 530 | 0.600 |
Why?
|
Leiomyoma | 1 | 2023 | 644 | 0.590 |
Why?
|
Testicular Neoplasms | 2 | 2024 | 805 | 0.580 |
Why?
|
Ribonuclease III | 3 | 2024 | 270 | 0.580 |
Why?
|
Ovary | 1 | 2021 | 960 | 0.560 |
Why?
|
Genital Neoplasms, Female | 1 | 2022 | 539 | 0.540 |
Why?
|
DEAD-box RNA Helicases | 3 | 2024 | 384 | 0.540 |
Why?
|
Nose Neoplasms | 1 | 2018 | 250 | 0.530 |
Why?
|
Mesothelioma | 1 | 2022 | 811 | 0.510 |
Why?
|
Peritoneal Neoplasms | 1 | 2022 | 715 | 0.500 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2018 | 725 | 0.470 |
Why?
|
Immunohistochemistry | 6 | 2024 | 11120 | 0.470 |
Why?
|
Papillomaviridae | 2 | 2023 | 1140 | 0.470 |
Why?
|
Endometriosis | 1 | 2022 | 875 | 0.450 |
Why?
|
Diagnosis, Differential | 6 | 2024 | 13020 | 0.390 |
Why?
|
Papillomavirus Infections | 2 | 2023 | 1640 | 0.380 |
Why?
|
Carcinoma, Squamous Cell | 5 | 2024 | 4069 | 0.380 |
Why?
|
Sinusitis | 1 | 2018 | 995 | 0.330 |
Why?
|
Cell Proliferation | 2 | 2024 | 10478 | 0.330 |
Why?
|
Cervix Uteri | 4 | 2024 | 577 | 0.280 |
Why?
|
Female | 32 | 2024 | 397089 | 0.270 |
Why?
|
Head and Neck Neoplasms | 1 | 2019 | 2923 | 0.240 |
Why?
|
Sertoli-Leydig Cell Tumor | 1 | 2024 | 21 | 0.230 |
Why?
|
Pulmonary Blastoma | 1 | 2024 | 43 | 0.230 |
Why?
|
Endodermal Sinus Tumor | 1 | 2024 | 53 | 0.220 |
Why?
|
Peritoneal Diseases | 1 | 2024 | 76 | 0.220 |
Why?
|
Neoplasms, Muscle Tissue | 1 | 2024 | 67 | 0.220 |
Why?
|
Kidney Pelvis | 1 | 2024 | 195 | 0.220 |
Why?
|
Poroma | 1 | 2022 | 9 | 0.210 |
Why?
|
Puberty, Precocious | 1 | 2024 | 166 | 0.210 |
Why?
|
Papilloma | 1 | 2023 | 143 | 0.210 |
Why?
|
Eccrine Porocarcinoma | 1 | 2022 | 18 | 0.210 |
Why?
|
Neural Cell Adhesion Molecule L1 | 1 | 2022 | 44 | 0.210 |
Why?
|
Sclerosis | 1 | 2023 | 212 | 0.210 |
Why?
|
Neoplasm Staging | 4 | 2024 | 11254 | 0.200 |
Why?
|
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2021 | 10 | 0.200 |
Why?
|
Galectin 3 | 1 | 2024 | 240 | 0.200 |
Why?
|
Isochromosomes | 1 | 2021 | 16 | 0.200 |
Why?
|
14-3-3 Proteins | 1 | 2023 | 222 | 0.200 |
Why?
|
Neoplasm Invasiveness | 3 | 2024 | 3633 | 0.200 |
Why?
|
Humans | 35 | 2024 | 768393 | 0.200 |
Why?
|
Predictive Value of Tests | 4 | 2024 | 15455 | 0.190 |
Why?
|
Prognosis | 7 | 2024 | 30022 | 0.190 |
Why?
|
Cyclin E | 1 | 2021 | 156 | 0.180 |
Why?
|
Cyclin D1 | 1 | 2023 | 453 | 0.180 |
Why?
|
Sweat Gland Neoplasms | 1 | 2022 | 111 | 0.180 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2024 | 9433 | 0.180 |
Why?
|
Diaphragm | 1 | 2022 | 359 | 0.180 |
Why?
|
Carcinoma, Endometrioid | 1 | 2023 | 276 | 0.180 |
Why?
|
Endometrium | 1 | 2023 | 407 | 0.170 |
Why?
|
Education, Distance | 1 | 2024 | 261 | 0.170 |
Why?
|
Orchiectomy | 1 | 2022 | 466 | 0.170 |
Why?
|
Fallopian Tube Neoplasms | 1 | 2022 | 329 | 0.170 |
Why?
|
Young Adult | 8 | 2024 | 60049 | 0.170 |
Why?
|
Adult | 16 | 2024 | 223640 | 0.160 |
Why?
|
Mutation | 3 | 2024 | 30228 | 0.160 |
Why?
|
BRCA2 Protein | 2 | 2021 | 802 | 0.160 |
Why?
|
Platinum | 1 | 2020 | 222 | 0.160 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2022 | 462 | 0.160 |
Why?
|
Aged | 14 | 2024 | 171562 | 0.160 |
Why?
|
Blood Proteins | 1 | 2024 | 1186 | 0.150 |
Why?
|
Lung Neoplasms | 2 | 2024 | 13576 | 0.150 |
Why?
|
Mentors | 1 | 2024 | 672 | 0.150 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2024 | 954 | 0.150 |
Why?
|
Tumor Burden | 1 | 2024 | 1913 | 0.150 |
Why?
|
Gynecology | 1 | 2024 | 533 | 0.150 |
Why?
|
Oncogene Proteins | 1 | 2021 | 718 | 0.140 |
Why?
|
Middle Aged | 14 | 2024 | 223491 | 0.140 |
Why?
|
Gene Dosage | 1 | 2021 | 1221 | 0.140 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2023 | 2524 | 0.140 |
Why?
|
Gene Deletion | 1 | 2024 | 2673 | 0.130 |
Why?
|
Child | 4 | 2024 | 80891 | 0.120 |
Why?
|
Adolescent | 5 | 2024 | 89184 | 0.100 |
Why?
|
Biological Products | 1 | 2021 | 934 | 0.100 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2021 | 2433 | 0.100 |
Why?
|
Tumor Suppressor Proteins | 1 | 2022 | 2812 | 0.100 |
Why?
|
Lymphatic Metastasis | 3 | 2024 | 2925 | 0.100 |
Why?
|
Recurrence | 1 | 2024 | 8506 | 0.100 |
Why?
|
Host-Pathogen Interactions | 1 | 2019 | 1468 | 0.090 |
Why?
|
Epithelial Cells | 1 | 2022 | 3695 | 0.090 |
Why?
|
Cell Cycle Proteins | 1 | 2021 | 3458 | 0.090 |
Why?
|
Pelvis | 2 | 2023 | 738 | 0.080 |
Why?
|
Genetic Predisposition to Disease | 2 | 2021 | 18048 | 0.070 |
Why?
|
Kidney Neoplasms | 1 | 2024 | 4303 | 0.070 |
Why?
|
Registries | 1 | 2024 | 8379 | 0.070 |
Why?
|
Aged, 80 and over | 4 | 2024 | 59686 | 0.070 |
Why?
|
Biopsy | 1 | 2018 | 6808 | 0.070 |
Why?
|
Mice, Inbred NOD | 2 | 2021 | 1839 | 0.070 |
Why?
|
Mice, SCID | 2 | 2021 | 2632 | 0.060 |
Why?
|
Models, Biological | 1 | 2021 | 9493 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2020 | 5336 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 1 | 2020 | 5708 | 0.060 |
Why?
|
Chronic Disease | 1 | 2018 | 9379 | 0.050 |
Why?
|
Asia | 1 | 2024 | 627 | 0.050 |
Why?
|
Rete Testis | 1 | 2022 | 10 | 0.050 |
Why?
|
Urothelium | 1 | 2024 | 276 | 0.050 |
Why?
|
Eccrine Glands | 1 | 2022 | 52 | 0.050 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2021 | 3617 | 0.050 |
Why?
|
Scrotum | 1 | 2022 | 118 | 0.050 |
Why?
|
Fallopian Tubes | 1 | 2022 | 179 | 0.050 |
Why?
|
Tumor Stem Cell Assay | 1 | 2021 | 116 | 0.050 |
Why?
|
Male | 6 | 2024 | 364902 | 0.050 |
Why?
|
Cell Line, Tumor | 3 | 2024 | 17135 | 0.050 |
Why?
|
Galectins | 1 | 2024 | 296 | 0.050 |
Why?
|
Pathology | 1 | 2024 | 270 | 0.050 |
Why?
|
North America | 1 | 2024 | 1290 | 0.050 |
Why?
|
Phenotype | 1 | 2018 | 16721 | 0.040 |
Why?
|
Retrospective Studies | 6 | 2024 | 81801 | 0.040 |
Why?
|
Risk Assessment | 1 | 2022 | 24318 | 0.040 |
Why?
|
S Phase | 1 | 2021 | 424 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2022 | 39407 | 0.040 |
Why?
|
Rad51 Recombinase | 1 | 2020 | 191 | 0.040 |
Why?
|
Pennsylvania | 1 | 2021 | 615 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11854 | 0.040 |
Why?
|
Hyperplasia | 1 | 2022 | 1153 | 0.040 |
Why?
|
Hormones | 1 | 2022 | 870 | 0.040 |
Why?
|
Cyclins | 1 | 2020 | 606 | 0.040 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2024 | 799 | 0.040 |
Why?
|
Europe | 1 | 2024 | 3439 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2020 | 13697 | 0.040 |
Why?
|
Gene Knockout Techniques | 1 | 2020 | 808 | 0.040 |
Why?
|
Lymph Node Excision | 1 | 2023 | 1274 | 0.040 |
Why?
|
Risk Factors | 1 | 2024 | 74962 | 0.030 |
Why?
|
Gender Identity | 1 | 2022 | 770 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2024 | 3553 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2023 | 1885 | 0.030 |
Why?
|
Apoptosis | 2 | 2021 | 9516 | 0.030 |
Why?
|
DNA Replication | 1 | 2021 | 1428 | 0.030 |
Why?
|
Drug Combinations | 1 | 2020 | 2079 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2024 | 6856 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 1 | 2024 | 6541 | 0.030 |
Why?
|
BRCA1 Protein | 1 | 2020 | 1155 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2023 | 2952 | 0.030 |
Why?
|
Periodicals as Topic | 1 | 2024 | 1469 | 0.030 |
Why?
|
Cell Movement | 1 | 2024 | 5215 | 0.020 |
Why?
|
Cell Survival | 1 | 2021 | 5792 | 0.020 |
Why?
|
Bone Marrow | 1 | 2021 | 2929 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2021 | 4921 | 0.020 |
Why?
|
Stem Cells | 1 | 2020 | 3539 | 0.020 |
Why?
|
Animals | 3 | 2024 | 169337 | 0.020 |
Why?
|
Mice | 2 | 2024 | 82017 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2023 | 20224 | 0.020 |
Why?
|
Incidence | 1 | 2023 | 21544 | 0.020 |
Why?
|
Time Factors | 1 | 2024 | 40272 | 0.010 |
Why?
|
Signal Transduction | 1 | 2021 | 23631 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2024 | 65379 | 0.010 |
Why?
|
Concepts
(171)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(34)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_